Your browser is no longer supported. Please, upgrade your browser.
KMPH KemPharm, Inc. daily Stock Chart
KemPharm, Inc.
Index- P/E- EPS (ttm)-0.89 Insider Own4.20% Shs Outstand49.00M Perf Week-13.01%
Market Cap15.17M Forward P/E- EPS next Y-0.03 Insider Trans5.39% Shs Float41.40M Perf Month-14.26%
Income-23.70M PEG- EPS next Q-0.09 Inst Own18.00% Short Float1.68% Perf Quarter-29.44%
Sales11.50M P/S1.32 EPS this Y-6.40% Inst Trans-4.10% Short Ratio0.53 Perf Half Y-65.21%
Book/sh-2.34 P/B- EPS next Y97.20% ROA-130.60% Target Price5.25 Perf Year-86.18%
Cash/sh0.13 P/C2.33 EPS next 5Y- ROE32.20% 52W Range0.26 - 2.57 Perf YTD-18.38%
Dividend- P/FCF- EPS past 5Y-7.50% ROI- 52W High-88.79% Beta1.24
Dividend %- Quick Ratio0.80 Sales past 5Y- Gross Margin91.30% 52W Low8.64% ATR0.04
Employees33 Current Ratio0.80 Sales Q/Q- Oper. Margin- RSI (14)38.03 Volatility10.84% 10.76%
OptionableYes Debt/Eq- EPS Q/Q110.30% Profit Margin- Rel Volume1.98 Prev Close0.31
ShortableYes LT Debt/Eq- EarningsMar 05 AMC Payout- Avg Volume1.32M Price0.29
Recom2.00 SMA20-19.85% SMA50-27.74% SMA200-66.84% Volume2,188,926 Change-7.01%
Sep-05-19Downgrade ROTH Capital Buy → Neutral $4.25 → $1.05
Sep-21-18Resumed Oppenheimer Outperform
Feb-26-18Reiterated Canaccord Genuity Buy $7 → $11
Jun-28-17Initiated ROTH Capital Buy $8
May-06-16Reiterated RBC Capital Mkts Outperform $22 → $14
Sep-18-15Reiterated Oppenheimer Outperform $20 → $28
Aug-14-15Reiterated RBC Capital Mkts Outperform $18 → $22
Jun-15-15Reiterated Canaccord Genuity Buy $18 → $22
May-11-15Initiated RBC Capital Mkts Outperform $18
May-11-15Initiated Canaccord Genuity Buy $18
Jan-29-20 12:30PM  3 Healthcare Stocks That Can Double This Year TipRanks +7.38%
Jan-15-20 08:30AM  Nasdaq Grants KemPharms Request for Extension to Comply with the Market Value of Listed Securities Continued Listing Requirement GlobeNewswire -9.43%
Dec-27-19 02:41PM  Virgin Trains financing among biggest Orlando economic development deals of the year American City Business Journals +14.44%
Dec-26-19 11:39AM  UPDATED: C. Fla. pharmaceutical firm enters debt restructure agreement American City Business Journals +30.12%
Dec-24-19 03:39PM  Central Florida pharmaceutical firm raises $71M American City Business Journals -9.02%
Dec-18-19 07:15AM  KemPharm Announces Debt Restructuring with Deerfield and Delaware Street Capital GlobeNewswire -7.89%
Dec-04-19 03:42PM  Edited Transcript of KMPH earnings conference call or presentation 14-Nov-19 10:30pm GMT Thomson Reuters StreetEvents
Nov-14-19 04:55PM  KemPharm Reports Third Quarter 2019 Results GlobeNewswire +7.75%
Nov-12-19 08:30AM  KemPharm to Report Third Quarter 2019 Results GlobeNewswire
Oct-31-19 08:30AM  KemPharm Reports APADAZ® Will be Available Nationally Beginning in November 2019 GlobeNewswire
Oct-22-19 04:15PM  KemPharm Presents Study Highlighting Patient-Friendly Dosing Properties of KP415 at the 66th Annual American Academy of Child & Adolescent Psychiatry Meeting GlobeNewswire
Oct-03-19 10:56AM  ArQule (ARQL) in Focus: Stock Moves 6.2% Higher Zacks
09:21AM  KemPharm, Inc. (NASDAQ:KMPH): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St.
Sep-20-19 05:00PM  KemPharm Provides Updates Regarding its Board of Directors GlobeNewswire
Sep-17-19 08:30AM  KemPharm to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma & Rare Diseases GlobeNewswire
Sep-04-19 01:55PM  Local pharmaceutical firm enters partnership valued up to $493M American City Business Journals -12.57%
08:00AM  KemPharm Announces Entry into Definitive Collaboration and License Agreement for its ADHD Candidates, KP415 and KP484, with an Affiliate of Gurnet Point Capital GlobeNewswire
Aug-13-19 05:00PM  KemPharm Reports Second Quarter 2019 Results GlobeNewswire -8.33%
Aug-07-19 10:59AM  Implied Volatility Surging for KemPharm (KMPH) Stock Options Zacks
Jul-05-19 10:13AM  Could The KemPharm, Inc. (NASDAQ:KMPH) Ownership Structure Tell Us Something Useful? Simply Wall St.
May-14-19 04:05PM  KemPharm Reports First Quarter 2019 Results GlobeNewswire
Apr-20-19 09:06AM  Penny Stocks to Buy Using Technical Analysis for April 2019 Investopedia
Apr-11-19 04:17PM  KemPharm Completes KP415 Pre-NDA Meeting with FDA GlobeNewswire
Mar-15-19 05:41PM  Edited Transcript of KMPH earnings conference call or presentation 28-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Mar-13-19 07:30AM  KemPharm Provides Update on APADAZ® Formulary Adoption GlobeNewswire
Mar-07-19 10:58AM  Loss-Making KemPharm, Inc. (NASDAQ:KMPH) Expected To Breakeven Simply Wall St.
Mar-05-19 07:30AM  KemPharm to Present at Upcoming Investor Conferences GlobeNewswire -5.48%
Feb-28-19 04:05PM  KemPharm Reports Q4 and FY 2018 Results GlobeNewswire -8.91%
02:30PM  KemPharm, Inc. to Host Earnings Call ACCESSWIRE
Feb-21-19 04:15PM  KemPharm to Report Fourth Quarter and Year End 2018 Results GlobeNewswire
Jan-29-19 07:30AM  KemPharm Announces Enhancements to U.S. and Global Intellectual Property Estate GlobeNewswire
Jan-21-19 10:44AM  What You Must Know About KemPharm, Inc.s (NASDAQ:KMPH) Beta Value Simply Wall St.
Jan-18-19 07:30AM  KemPharm Presenting Four Scientific Posters at APSARD's 2019 Annual Meeting GlobeNewswire
Jan-07-19 07:30AM  KemPharm Announces FDA Approval of sNDA for Two Additional Strengths of APADAZ® (4.08 mg benzhydrocodone/325 mg APAP and 8.16 mg benzhydrocodone/325 mg APAP) GlobeNewswire
Jan-02-19 07:30AM  New Research: Key Drivers of Growth for Hewlett Packard Enterprise, Micron Technology, Cirrus Logic, Applied Genetic Technologies, KemPharm, and Communications Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire +11.24%
Dec-19-18 07:30AM  KemPharm Provides Corporate Update on Partnering Process for ADHD Prodrug Portfolio GlobeNewswire -5.53%
Dec-12-18 07:30AM  KemPharm Presents Poster at ACNPs 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX) GlobeNewswire
Dec-11-18 08:08AM  KemPharm Webcast on Now Available for On-Demand Viewing PR Newswire
Dec-04-18 08:35AM  Live Investor Conference & Webinar: NYSE, NASDAQ, and OTC companies present December 6th PR Newswire
Dec-03-18 07:30AM  KemPharm to Webcast Live at on December 6th PR Newswire
Nov-26-18 02:44PM  What Kind Of Shareholders Own KemPharm Inc (NASDAQ:KMPH)? Simply Wall St. -7.22%
Nov-21-18 08:55AM  Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Nov-20-18 09:31PM  Edited Transcript of KMPH earnings conference call or presentation 8-Nov-18 9:30pm GMT Thomson Reuters StreetEvents -6.25%
Nov-13-18 07:30AM  KemPharm Enhances Pipeline with the Addition of KP879, a Potential New Treatment for Stimulant Use Disorder GlobeNewswire
Nov-08-18 04:05PM  KemPharm, Inc. Reports Third Quarter 2018 Results GlobeNewswire
Nov-01-18 07:30AM  KemPharm to Report Third Quarter 2018 Results GlobeNewswire +10.19%
Oct-30-18 04:05PM  KemPharm Enters Into License Agreement with KVK Tech for the Commercialization of APADAZ® GlobeNewswire
Oct-24-18 07:30AM  KemPharm Presents Data from Intranasal and Intravenous Human Abuse Potential Trials of KP415 Prodrug at the American Academy of Child & Adolescent Psychiatry Meeting GlobeNewswire -18.07%
Oct-23-18 07:30AM  KemPharm and twoXAR Announce Technology Collaboration to Develop Prodrug-Based Therapies for Multiple Indications GlobeNewswire
Oct-11-18 04:05PM  KemPharm Provides Highlights from KOL Investor Event Focused on the ADHD Treatment Landscape GlobeNewswire
Oct-05-18 10:01AM  Aytu, KemPharm stocks plunge to pace Nasdaq decliners after share offerings MarketWatch -36.36%
09:24AM  KemPharm Announces Pricing of Public Offering of Common Stock GlobeNewswire
Oct-04-18 04:07PM  KemPharm Announces Proposed Public Offering of Common Stock GlobeNewswire
Oct-03-18 04:41PM  KemPharm to Host KOL Investor Event Focused on the ADHD Treatment Landscape GlobeNewswire
Sep-17-18 07:30AM  KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug GlobeNewswire -5.83%
Sep-12-18 10:12AM  KemPharm Posts Positive Top-Line Results on KP415 Prodrug Zacks +6.19%
Sep-11-18 07:30AM  KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug GlobeNewswire -7.18%
Sep-05-18 07:30AM  KemPharm to Present at Two Healthcare Investor Conferences During September 2018 GlobeNewswire
Aug-09-18 04:05PM  KemPharm, Inc. Reports Second Quarter 2018 Results GlobeNewswire
Aug-01-18 07:30AM  KemPharm to Present at Canaccord Genuity 38th Annual Growth Conference GlobeNewswire +7.32%
Jul-31-18 07:30AM  KemPharm, Inc. to Report Second Quarter 2018 Results GlobeNewswire +5.13%
Jul-17-18 08:41AM  Options Traders Expect Huge Moves in KemPharm (KMPH) Stock Zacks
Jul-10-18 10:37AM  KemPharm Stock Down Despite Positive Data on ADHD Candidate Zacks -11.20%
Jul-09-18 12:46PM  Groupon may be looking for a buyer, Boeing strikes major deal, KemPharm soars on drug test results Yahoo Finance Video -7.41%
11:42AM  KemPharm's ADHD Candidate Meets Efficacy, Safety Trial Endpoints Benzinga
08:31AM  Trump to reshape Supreme Court for decades to come Yahoo Finance Video
07:20AM  Yahoo Finance Live: Market Movers - Jul 9th, 2018 Yahoo Finance Video
07:13AM  KemPharm's stock soars after ADHD drug trial meets primary endpoints MarketWatch
07:00AM  KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD GlobeNewswire
May-23-18 12:00PM  Janney Buys Into KemPharm Ahead Of 'Transformative' Summer Catalyst Benzinga
May-18-18 11:07AM  Who Are The Major Shareholders In KemPharm Inc (NASDAQ:KMPH)? Simply Wall St.
May-11-18 01:40PM  KemPharm Stock Breaks Out on Clinical Trial Results Investopedia +11.32%
May-10-18 09:07PM  Will KemPharm Incs (NASDAQ:KMPH) Earnings Grow Over The Next Few Years? Simply Wall St.
04:05PM  KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug; Reports Q1 2018 Results GlobeNewswire
May-01-18 07:30AM  KemPharm, Inc. to Report First Quarter 2018 Results GlobeNewswire
Apr-23-18 07:30AM  Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine ACCESSWIRE
Mar-29-18 08:47PM  Breakeven On The Horizon For KemPharm Inc (NASDAQ:KMPH) Simply Wall St.
04:05PM  KemPharm Reports Fourth Quarter and Year End 2017 Results GlobeNewswire
12:00PM  KemPharm, Inc. to Host Earnings Call ACCESSWIRE
Mar-21-18 07:30AM  KemPharm, Inc. to Report Fourth Quarter and Year End 2017 Results GlobeNewswire +14.29%
Mar-20-18 07:30AM  KemPharm Announces Positive Topline Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD GlobeNewswire +6.06%
Mar-06-18 07:30AM  KemPharm to Present at Upcoming Investor Conferences GlobeNewswire
Mar-05-18 04:35PM  At $6, Is KemPharm Inc (NASDAQ:KMPH) A Buy? Simply Wall St.
Feb-26-18 10:06AM  Heres Whats Moving KemPharm And Puma Biotechnology Market Exclusive
Feb-23-18 03:38PM  KemPharm's opioid painkiller gets FDA approval, shares soar Reuters +14.03%
02:00PM  FDA approves KemPharm's opioid painkiller Reuters
02:00PM  KemPharm Announces FDA Approval of Apadaz (benzhydrocodone and acetaminophen) for the Short-Term Management of Acute Pain GlobeNewswire
Feb-19-18 03:31PM  Why KemPharm Incs (NASDAQ:KMPH) CEO Salary Matters To You Simply Wall St.
Feb-13-18 07:30AM  KemPharm to Present at the RBC Capital Markets 2018 Global Healthcare Conference GlobeNewswire
Jan-31-18 07:30AM  KemPharm to Present at The MoneyShow Orlando Investor Conference GlobeNewswire
Jan-25-18 07:50AM  Blog Exposure - KemPharm Announces Patent Grant for KP606 and KP511-Related Family ACCESSWIRE
Jan-23-18 07:30AM  KemPharm Receives Patent Grant for KP606, a Prodrug of Oxycodone GlobeNewswire
Jan-08-18 07:30AM  KemPharm Initiates Pivotal Efficacy Trial of KP415 GlobeNewswire
Dec-12-17 02:14PM  Should You Be Concerned About KemPharm Incs (undefined:KMPH) Investors? Simply Wall St.
Nov-16-17 07:30AM  KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA GlobeNewswire
Nov-09-17 04:05PM  KemPharm Reports Third Quarter 2017 Results and Provides Corporate Update GlobeNewswire
08:15AM  How Much is KemPharm Incs (KMPH) CEO Getting Paid? Simply Wall St.
Nov-06-17 07:30AM  KemPharm Receives USAN Approval for Asalhydromorphone as Nonproprietary Name for Novel Prodrug Candidate, KP511 GlobeNewswire
Nov-02-17 07:30AM  KemPharms KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate, Allowed to Proceed to Clinical Studies GlobeNewswire
Nov-01-17 04:30PM  KemPharm, Inc. to Report Third Quarter 2017 Results GlobeNewswire
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. The company's product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. It also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. The company has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. KemPharm, Inc. was founded in 2006 and is headquartered in Celebration, Florida.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Johnson Gordon KChief Business OfficerDec 31Buy0.3920,0007,78440,000Jan 02 04:45 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerDec 27Buy0.4212,2505,11025,000Dec 30 04:26 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerSep 25Buy0.753,6502,72012,750Sep 25 08:58 PM
Sangiovanni Timothy J.VP, Corporate ControllerSep 24Buy0.743,0002,2206,000Sep 25 08:57 PM
Mickle Travis CPresident & CEOSep 24Buy0.7950,00039,3821,753,117Sep 24 08:25 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerSep 16Buy0.895,0004,4259,100Sep 16 04:59 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerSep 11Buy0.955004734,100Sep 11 04:50 PM
Johnson Gordon KChief Business OfficerSep 09Buy0.8210,0008,16820,000Sep 09 04:12 PM
Clifton R. LaDuaneCFO, Secretary & TreasurerSep 06Buy0.778506523,600Sep 06 05:06 PM